San Francisco – The jury found that a man had developed cancer by exposing a raid he used in his yard, in the second case to sue for the alleged damage to the popular
The six-member jury at the US District Court in San Francisco will now begin hearing evidence to weigh separately the Bayer Monsanto unit
The original verdict marks yet another failure for Bayer, which is under intense pressure after the jury in August reached a $ 289.2 million conviction in the first case against the weed killer. go to the process. This sentence ended shortly after the acquisition of Monsanto by Bayer.
Analysts and investors saw Bayer taking advantage of this second trial after US District Judge Vince Chabria agreed to divide the evidence into two phases. whether Roundup and its active ingredient, glyphosate, are carcinogenic
Bayer is facing lawsuits from around 1
Lawyers for plaintiff Edwin Hardman says he has developed non-Hodgkin's lymphoma after 26 years of regular use of Roundup to control weeds and poison oak in his rural property in northern California.
"We showed you the evidence that Monsanto refuses to analyze," Wagstaf told the jury at the closing arguments. Ms Wagstaff argues that Monsanto ignores animal studies and cellular structures that, along with human populations, prove the dangers of Roundup. "Do not overlook the data that Monsanto wants to ignore," she said.
Bayer's lawyer Brian Steflof opposes in his concluding remarks that scientific jurors are shown to be court and that the experts do not warn anyone about the alleged damage to Roundup in their working days. "They tell you that real world practice does not matter," he said about the position of the plaintiff. Bayer argues that about 800 studies and regulatory decisions around the world claim that glyphosate is safe and not carcinogenic. Bayer's CEO Werner Baumann said last month that the two-phase process would allow Bayer to place a strong emphasis on scientific data confirming product safety
In 2015, the International Agency for Research on Cancer, a branch of the World Health Organization , called glyphosate, probably carcinogenic for humans. This has begun a wave of lawsuits and regulatory scrutiny around the world.
Before the first trial, plaintiff Deane Johnson, a former school teacher, issued internal Monsanto emails that said they showed the company's inadequate role in studying glyphosate studies, Bayer argued that these emails were removed from Context
Johnson's lawyers claim in court that Monsanto knew that testing for glyphosate was inadequate, and that employees began writing good scientific papers and paid outside scholars to publish the articles under their names. The San Francisco State Court jury found that Monsanto knew or ought to have known about the potential risks and had not warned consumers. Bayer appealed the verdict that the judge cut to $ 78.5 million.
The lawsuit in progress in San Francisco will now go into the second phase, examining Monsanto's behavior and whether it is casual.
what evidence could enter the first phase caused court clashes, including $ 500 penalties against the plaintiff's lead attorney for what the judge calls obvious violations of his orders as to what the jury can see. Hardman's case is the first of three trials to be held at the federal court to help assess claims. Hundreds of federal cases were consolidated before Judge Chhabria
Mr. In February, Bowman warned that the legal fight against glyphosis was "just beginning." Analysts say they will have to see at least a few sentences before they can make more accurate estimates of potential Bayer's obligations. Until this happens, stocks will probably be depressed, they say. Sara Randaso at email@example.com and Ruth Bender at Ruth.Bender@wsj.com